Overview

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment

Status:
Completed
Trial end date:
2023-10-07
Target enrollment:
Participant gender:
Summary
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of Leritrelvir(RAY1216)
Phase:
Phase 1
Details
Lead Sponsor:
Guangdong Raynovent Biotech Co., Ltd